Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06235580 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06235580 · ClinicalTrials.gov record · last posted 2025-12-19

Genotype-phenotype Characterization Study on Genetic Diseases With Immune and Neurological Dysfunctions

Study acronym: IFN
StatusRecruiting
PhaseNot specified
Started2015-12-28
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
Over the past twenty years, Prof. Yanick Crow and his team have developed internationally recognized expertise in genetic pathologies affecting the immune and neurological systems. The pathologies studied have a particularly severe impact on patients' quality of life, with a high mortality rate and a significant risk of occurrence in affected families. These pathologies are rare, and very often under-diagnosed. To date, there is virtually no effective curative treatment. Prof. Crow's team operates at the frontier between clinical and research work, and from experience, the team knows that patients and families affected by these serious pathologies are often highly motivated to help research into the pathology that affects them. Initially, Prof. Crow's research focused primarily on the study of the genetic disease Aicardi-Goutières Syndrome (AGS). However, there is an undeniable clinical and pathological overlap between AGS and other forms of disease such as autoimmune systemic lupus erythematosus and many other genetic pathologies - e.g. familial lupus engelure, spondyloenchondromatosis and COPA syndrome. This is why research is being extended to all genetic diseases with immune and neurological dysfunctions.

Amendment record 2 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 2 times since 2024-01-23; most recent amendment 2025-12-12. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

Trial Details
NCT Number NCT06235580
Lead Sponsor Imagine Institute
Conditions Genetic Diseases, Immune Dysfunction, Neurological Disease, Autoimmune Diseases
Enrollment 1,000 participants
Start Date 2015-12-28
Primary Completion 2030-12-27 (estimated)
Study Completion 2035-12-27 (estimated)
Updated on ClinicalTrials.gov 2025-12-19